Daxor Corporation DXR

Daxor Corporation receives U.S. patent for breakthrough remote blood volume monitor. Patent secures exclusive rights to core remote monitoring technology that can shift competitive positioning and revenue potential.

New clinical data presented at SCCM 2026 validates Daxor’s blood volume analysis metric as uniquely accurate versus capillary leak indexes. Clinical validation positions Daxor's metric as superior in accuracy, boosting competitive standing and market potential.

Daxor Corporation will showcase its next-generation portable blood volume analyzer at ACC.26, highlighting clinical outcomes and reduced hospital readmissions. Showcasing next-generation portable analyzer at major cardiology conference signals product advancement poised to enhance clinical adoption and investor sentiment.

Daxor Corporation showcased its portable FDA-cleared Blood Volume Analyzer and 'Razor-and-Blades' kit growth strategy at iAccess Alpha. Highlighting a portable FDA-cleared analyzer with recurring 'razor-and-blades' revenue model represents a major strategic product push likely to enhance competitive positioning and investor interest.

Daxor Corporation will debut its new rapid, portable blood volume analyzer at the SCCM 2026 Critical Care Congress. Debut of a new rapid, portable blood volume analyzer at a key critical care congress represents a significant product launch poised to enhance Daxor's competitive edge and market performance.

Daxor Corporation reported 2025 fiscal year results with operating revenue up 45% and net asset value rising to $9.07 per share. 45% operating revenue growth and net asset value increase to $9.07 per share represent major financial gains poised to significantly enhance investor sentiment and company trajectory.

Daxor Corporation CEO and President Michael Feldschuh issued a letter to shareholders with a corporate update. CEO's shareholder letter delivers operational updates with moderate potential to influence Daxor's financial performance and investor sentiment.

Daxor Corporation expands outpatient services by launching a Blood Volume Analysis (BVA) diagnostic program in Tennessee. Launching a BVA diagnostic program in Tennessee marks a significant strategic expansion of outpatient presence, enhancing revenue potential and market positioning.

Daxor Corporation has announced its transition to a reporting company under the Securities Exchange Act of 1934. This move reaffirms the company's commitment to its core business in blood volume analysis and diagnostics, aiming to enhance transparency and investor confidence. Transitioning to a reporting company may improve investor relations and market perception, but its overall impact on financial performance is expected to be limited.

Daxor Corporation has announced a registered direct offering of $9 million. The offering is expected to be completed shortly, with the proceeds intended for general corporate purposes, including working capital and potential investments in growth opportunities. The company aims to enhance its financial position through this capital raise. The capital raise may provide Daxor with necessary funds for growth, but its overall impact on long-term performance remains limited.

Daxor Corporation has announced the adoption of three new facilities and the deployment of its next-generation BVA Analyzer, aimed at enhancing its operational capabilities and expanding its market presence. These strategic moves are expected to support the company's growth and improve its product offerings in the medical diagnostics sector. The introduction of new facilities and advanced technology is likely to significantly impact Daxor's operational efficiency and market competitiveness.

Daxor Corporation's CEO, Michael Feldschuh, is set to engage with investors at the exclusive Maxim Growth Summit. This event presents an opportunity for the company to showcase its innovations and growth strategies to potential investors, aiming to enhance investor relations and market presence. Engagement at investor summits can moderately influence market sentiment and investor interest in the company's future prospects.

Daxor Corporation will showcase its new BVA technology at the MedAxiom CV Transforum Fall '25. This event highlights advancements in cardiovascular care and aims to enhance patient outcomes through innovative medical technologies. The introduction of new technology at a prominent industry event is likely to significantly impact Daxor's market positioning and investor sentiment.

Daxor Corporation has launched its new FDA-cleared BVA Analyzer, responding to strong market demand and supported by pivotal clinical data presented at the Heart Failure Society of America (HFSA) conference. This innovative device aims to enhance patient care by providing accurate blood volume assessments, which are crucial for managing heart failure and other related conditions. The launch of the FDA-cleared BVA Analyzer is a significant strategic move that could enhance Daxor's market position and investor sentiment.

Daxor Corporation has introduced its next-generation BVA Analyzer at the HFSA Annual Scientific Meeting, showcasing advancements in blood volume analysis technology. This new device aims to enhance patient care by providing more accurate and timely assessments, potentially improving outcomes for heart failure patients. The launch reflects Daxor's commitment to innovation in the medical technology sector. The introduction of a next-gen BVA Analyzer is a significant strategic move that could enhance Daxor's competitive position and market presence.

Daxor Corporation's blood volume analysis has been validated for use in COVID and sepsis patients, according to a new peer-reviewed pilot study published in the Journal of Critical Care. The study demonstrates the effectiveness of Daxor's technology in accurately assessing blood volume, which is crucial for managing critically ill patients. This validation could enhance the company's position in the healthcare market, particularly in critical care settings. Validation of Daxor's technology for critical conditions like COVID and sepsis is likely to significantly enhance its market position and investor sentiment.

Daxor Corporation (DXR) announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, where it will present its latest developments and strategic initiatives to investors and analysts. The conference serves as a platform for the company to engage with stakeholders and showcase its advancements in medical technology and blood volume measurement. Participation in a significant investment conference may enhance investor interest and market visibility, but the immediate impact on financial performance is expected to be limited.

Daxor Corporation CEO Michael Feldschuh provided a corporate update in a letter to shareholders, highlighting the company's recent developments and strategic initiatives. The letter outlines progress in product innovation and market positioning, emphasizing the importance of ongoing research and development efforts. Feldschuh also addressed financial performance and future growth prospects, reassuring shareholders of the company's commitment to enhancing shareholder value. The update indicates moderate progress in key areas that could influence financial performance and market sentiment.

Daxor Corporation has received FDA clearance for its new rapid and lightweight blood volume analysis system. This innovative technology is designed to enhance the accuracy and efficiency of blood volume measurement, potentially improving patient care in various medical settings. The FDA clearance marks a significant milestone for Daxor, as it aims to expand its product offerings and strengthen its position in the healthcare market. FDA clearance for a new medical device can significantly enhance Daxor's market position and revenue potential.

Daxor Corporation (Nasdaq: DXR) has expanded its blood volume analysis technology into three new hospitals, highlighting the growing recognition of its importance in healthcare. The adoption of Daxor's ezBVA Lab service and on-site analyzers is expected to drive accelerated sales growth throughout 2025 as clinicians increasingly utilize blood volume analysis for fluid management. Recent adoptions include a Tennessee medical center, a major Arkansas hospital, and a leading referral hospital serving Arizona, Nevada, and Utah, all integrating Daxor's technology for advanced heart care applications. Expansion into multiple hospitals indicates significant market acceptance and potential for increased sales growth.

Daxor Corporation announced findings from a Duke University study published in the American Heart Journal, demonstrating the effectiveness of Blood Volume Analysis (BVA) in identifying true anemia versus dilutional anemia in heart failure patients. The study revealed that 60% of heart failure patients diagnosed with anemia had true anemia, while 40% had dilutional pseudo-anemia. This differentiation is crucial for treatment decisions, as only truly anemic patients require red cell therapy. The research underscores the importance of BVA in heart failure management, potentially impacting patient outcomes and quality of life. The study's findings could significantly influence treatment approaches and patient management in heart failure, enhancing Daxor's market position.

Daxor Corporation (Nasdaq: DXR) has expanded its blood volume measurement technology into two new U.S. healthcare systems, enhancing care for cardiovascular and critical care patients. A regional referral center in East Tennessee has integrated Daxor's ezBVA Lab service, providing diagnostic results within 24 hours. Meanwhile, a healthcare facility in the Pacific Northwest has implemented an on-site BVA analyzer system for immediate access to blood volume data. These advancements aim to optimize patient outcomes and demonstrate the versatility of Daxor's solutions, which have been clinically proven to reduce mortality and hospital readmissions. The expansion into new healthcare systems represents a significant strategic move that could enhance Daxor's market position and financial performance.

Daxor Corporation has launched a new blood volume analysis program at a healthcare center in Florida, enhancing fluid management in patient care. The facility will use Daxor's CLIA-certified ezBVA Lab, providing results within 24 hours. CEO Michael Feldschuh emphasized the importance of precise volume assessment for improving treatment outcomes and reducing costs. Daxor's technology offers 98% accuracy in blood volume measurements, supporting various medical conditions. The service is fully reimbursable through insurance plans, marking a significant milestone in Daxor's expansion efforts. The launch of the BVA program and the integration of advanced technology are likely to significantly enhance Daxor's market position and financial performance.

Daxor Corporation (Nasdaq: DXR) announces the expansion of its blood volume analysis capabilities with the adoption of its ezBVA Lab service in three new hospitals. This CLIA-certified service provides precise blood volume analysis results within 24 hours, enhancing outpatient heart failure management. The service's zero-capital investment model and full reimbursement coverage have driven strong sales momentum, with healthcare providers recognizing its benefits in improving patient outcomes and operational efficiency. Daxor's BVA-100® is the only FDA-cleared diagnostic blood test for quantifying blood volume status, with over 70,000 tests performed across the U.S. Daxor is also involved in ongoing trials for heart failure treatment and developing analyzers for the U.S. Department of Defense. The expansion of Daxor's services and the adoption of its technology by multiple hospitals are likely to significantly enhance its market position and financial performance.

Daxor Corporation (Nasdaq: DXR) will exhibit its blood volume analysis technology at the 45th International Society for Heart and Lung Transplantation Annual Meeting from April 27-30, 2025, in Boston, MA. CEO Michael Feldschuh emphasized the technology's 98% accuracy in providing personalized treatment for end-stage heart and lung patients, which can improve outcomes and reduce costs. Daxor's BVA-100® is the only FDA-cleared diagnostic for quantifying blood volume status. The company has conducted over 65,000 tests and is involved in ongoing trials for heart failure treatment with NIH support, as well as developing analyzers for the U.S. Department of Defense. Daxor aims to enhance healthcare through optimal fluid management. Participation in a major medical conference and showcasing innovative technology can significantly enhance Daxor's market presence and investor sentiment.

Daxor Corporation (Nasdaq: DXR) will showcase its blood volume analysis technology at the MedAxiom CV Transforum Spring’25 Conference in Orlando, FL, from April 24-26, 2025. Wellstar Health System's Dr. Brian Howard will present a study demonstrating how blood volume analysis (BVA) significantly reduced acute kidney injury rates following left ventricular assist device implantation. BVA has been shown to improve patient outcomes, including reductions in mortality and hospital readmissions. Daxor's BVA-100® is the only FDA-cleared diagnostic test for blood volume measurement, with over 65,000 tests performed in the U.S. Daxor aims to enhance healthcare through optimal fluid management and is involved in ongoing trials supported by the NIH and the U.S. Department of Defense. The presentation of significant clinical findings and the focus on BVA technology could lead to increased adoption and market growth for Daxor's products.

Daxor Corporation announced new research at the ACC 74th Annual Scientific Session showing that blood volume analysis (BVA) can significantly improve survival rates for hospitalized heart failure patients. The study evaluated 1,237 patients, revealing that those identified as euvolemic through BVA had a 2.61 times better one-year survival rate compared to hypervolemic patients. The findings support the clinical value of BVA in optimizing treatment and improving outcomes for heart failure patients, reinforcing Daxor's position as a leader in blood volume measurement technology. The study's findings could significantly enhance Daxor's market position and investor sentiment by validating the effectiveness of its BVA technology in improving patient outcomes.

Daxor Corporation has submitted its next-generation blood volume analyzer, the Daxor BVA, to the FDA, aiming to enhance healthcare through improved fluid management. The new device is designed to be three times faster, simpler to operate, portable, and suitable for point-of-care analysis. CEO Michael Feldschuh highlighted its potential to significantly improve medical care and patient outcomes. Daxor, a leader in blood volume measurement technology, has previously developed the BVA-100® system and has conducted over 65,000 tests in U.S. hospitals, focusing on heart failure and critical care. The company is also involved in ongoing trials and contracts with the U.S. Department of Defense. The submission of a next-generation analyzer to the FDA represents a significant strategic move that could enhance Daxor's market position and investor sentiment.

Daxor Corporation announced new data from Duke University and highlighted key insights from its Blood Volume Analyzer (BVA) at the American College of Cardiology’s 74th Annual Scientific Session and Expo. The presentation focused on the importance of blood volume measurement in managing heart failure and other cardiovascular conditions, showcasing the BVA's potential to improve patient outcomes and guide treatment decisions. The presentation of new data and insights at a major medical conference could significantly enhance Daxor's market position and investor sentiment regarding its innovative technology.

Daxor Corporation is expanding its blood volume analysis technology across healthcare networks in the Midwest, specifically in Wisconsin and New Jersey. This expansion aims to enhance patient care and improve clinical outcomes by providing more accurate blood volume measurements, which are crucial for various medical conditions. The initiative is expected to strengthen Daxor's presence in these regions and potentially increase its market share. Expansion into new healthcare networks is likely to significantly enhance Daxor's market presence and revenue potential.